KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentBeginning Cash BalanceBeginning Cash BalanceCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in IntangiblesChange in IntangiblesChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionDivestmentsExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Depreciation & Amortization (CF) (2017 - 2026)

Amneal Pharmaceuticals has reported Depreciation & Amortization (CF) over the past 9 years, most recently at $49.2 million for Q4 2025.

  • For Q4 2025, Depreciation & Amortization (CF) fell 25.56% year-over-year to $49.2 million; the TTM value through Dec 2025 reached $223.6 million, down 5.34%, while the annual FY2025 figure was $223.6 million, 5.34% down from the prior year.
  • Depreciation & Amortization (CF) for Q4 2025 was $49.2 million at Amneal Pharmaceuticals, down from $54.1 million in the prior quarter.
  • Over five years, Depreciation & Amortization (CF) peaked at $66.1 million in Q4 2024 and troughed at $49.2 million in Q4 2025.
  • A 5-year average of $58.1 million and a median of $58.0 million in 2022 define the central range for Depreciation & Amortization (CF).
  • Biggest five-year swings in Depreciation & Amortization (CF): grew 16.15% in 2024 and later fell 25.56% in 2025.
  • Year by year, Depreciation & Amortization (CF) stood at $61.2 million in 2021, then decreased by 0.21% to $61.1 million in 2022, then dropped by 6.75% to $56.9 million in 2023, then rose by 16.15% to $66.1 million in 2024, then fell by 25.56% to $49.2 million in 2025.
  • Business Quant data shows Depreciation & Amortization (CF) for AMRX at $49.2 million in Q4 2025, $54.1 million in Q3 2025, and $60.1 million in Q2 2025.